ATE365155T1 - 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten - Google Patents
1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheitenInfo
- Publication number
- ATE365155T1 ATE365155T1 AT04765174T AT04765174T ATE365155T1 AT E365155 T1 ATE365155 T1 AT E365155T1 AT 04765174 T AT04765174 T AT 04765174T AT 04765174 T AT04765174 T AT 04765174T AT E365155 T1 ATE365155 T1 AT E365155T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- inflammatory
- ccr
- azetided
- disubstituted
- Prior art date
Links
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 102000004499 CCR3 Receptors Human genes 0.000 title 1
- 108010017316 CCR3 Receptors Proteins 0.000 title 1
- 230000000172 allergic effect Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 208000010668 atopic eczema Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010027654 Allergic conditions Diseases 0.000 abstract 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 abstract 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 abstract 1
- 208000027771 Obstructive airways disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0321600A GB0321600D0 (en) | 2003-09-15 | 2003-09-15 | Organic compounds |
| GB0321599A GB0321599D0 (en) | 2003-09-15 | 2003-09-15 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE365155T1 true ATE365155T1 (de) | 2007-07-15 |
Family
ID=34315436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04765174T ATE365155T1 (de) | 2003-09-15 | 2004-09-14 | 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20070043013A1 (de) |
| EP (1) | EP1663966B1 (de) |
| JP (2) | JP2007505080A (de) |
| AT (1) | ATE365155T1 (de) |
| AU (1) | AU2004272275B2 (de) |
| BR (1) | BRPI0414416A (de) |
| CA (1) | CA2534550A1 (de) |
| DE (1) | DE602004007150T2 (de) |
| ES (1) | ES2286664T3 (de) |
| MX (1) | MXPA06002870A (de) |
| PL (1) | PL1663966T3 (de) |
| PT (1) | PT1663966E (de) |
| WO (1) | WO2005026113A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417801D0 (en) * | 2004-08-10 | 2004-09-15 | Novartis Ag | Organic compounds |
| JP5313881B2 (ja) | 2007-04-04 | 2013-10-09 | 興和株式会社 | テトラヒドロイソキノリン化合物 |
| US10160727B2 (en) | 2014-08-06 | 2018-12-25 | Shionogi & Co., Ltd. | Heterocycle and carbocycle derivatives having TrkA inhibitory activity |
| US10640495B2 (en) | 2015-07-07 | 2020-05-05 | Shionogi & Co., Ltd. | Heterocycle derivatives having TrkA inhibitory activity |
| EP3412663B1 (de) | 2016-02-04 | 2022-09-07 | Shionogi & Co., Ltd. | Stickstoffhaltige heterozyklische und carbozyklische derivate mit trka-hemmender wirkung |
| CN110498750B (zh) * | 2019-09-02 | 2021-10-15 | 南通大学 | 一种(r)-4-羟基-1-甲氧基丁-2-基氨基甲酸叔丁酯的合成方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8509746D0 (en) * | 1985-04-16 | 1985-05-22 | Shell Int Research | Preparing azetidine derivatives |
| WO1999004794A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| US6444686B1 (en) * | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1156807A4 (de) * | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| EP1363881A2 (de) * | 2000-06-21 | 2003-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidine zur verwendung als chemokin-receptor-modulatoren |
| GB0117387D0 (en) * | 2001-07-17 | 2001-09-05 | Novartis Ag | Organic compounds |
| TW200305395A (en) * | 2002-03-15 | 2003-11-01 | Novartis Ag | Organic compounds |
-
2004
- 2004-09-14 BR BRPI0414416-3A patent/BRPI0414416A/pt not_active IP Right Cessation
- 2004-09-14 AT AT04765174T patent/ATE365155T1/de not_active IP Right Cessation
- 2004-09-14 PL PL04765174T patent/PL1663966T3/pl unknown
- 2004-09-14 EP EP04765174A patent/EP1663966B1/de not_active Expired - Lifetime
- 2004-09-14 CA CA002534550A patent/CA2534550A1/en not_active Abandoned
- 2004-09-14 US US10/568,486 patent/US20070043013A1/en not_active Abandoned
- 2004-09-14 AU AU2004272275A patent/AU2004272275B2/en not_active Ceased
- 2004-09-14 PT PT04765174T patent/PT1663966E/pt unknown
- 2004-09-14 WO PCT/EP2004/010260 patent/WO2005026113A1/en not_active Ceased
- 2004-09-14 MX MXPA06002870A patent/MXPA06002870A/es active IP Right Grant
- 2004-09-14 ES ES04765174T patent/ES2286664T3/es not_active Expired - Lifetime
- 2004-09-14 JP JP2006525789A patent/JP2007505080A/ja not_active Ceased
- 2004-09-14 DE DE602004007150T patent/DE602004007150T2/de not_active Expired - Lifetime
-
2010
- 2010-06-23 JP JP2010143023A patent/JP2010265278A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010265278A (ja) | 2010-11-25 |
| CA2534550A1 (en) | 2005-03-24 |
| PT1663966E (pt) | 2007-09-26 |
| PL1663966T3 (pl) | 2007-11-30 |
| AU2004272275B2 (en) | 2009-02-26 |
| EP1663966B1 (de) | 2007-06-20 |
| ES2286664T3 (es) | 2007-12-01 |
| AU2004272275A1 (en) | 2005-03-24 |
| WO2005026113A1 (en) | 2005-03-24 |
| EP1663966A1 (de) | 2006-06-07 |
| MXPA06002870A (es) | 2006-06-05 |
| US20070043013A1 (en) | 2007-02-22 |
| DE602004007150T2 (de) | 2008-02-14 |
| DE602004007150D1 (de) | 2007-08-02 |
| BRPI0414416A (pt) | 2006-11-14 |
| JP2007505080A (ja) | 2007-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60333371D1 (de) | 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen | |
| DE602004011199D1 (de) | 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren | |
| NO20055714L (no) | Inhibitorer av fosfatidylinositol 3-kinase | |
| ATE402935T1 (de) | Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen | |
| MY156407A (en) | 5-phenylthiazole derivatives and use as p13 kinase inhibitors | |
| DE60322713D1 (de) | Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung | |
| CY1109227T1 (el) | Παραγωγα της 5-φαινυλο-4-μεθυλο-θειαζολ-2-υλ-αμινης ως αναστολεις των ενζυμων κινασης της φωσφατιδυλινοσιτολης 3 (p13) για την θεραπεια των φλεγμονωδων ασθενειων των αεραγωγων | |
| DE60226729D1 (de) | Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| PL1891029T3 (pl) | Związki organiczne do leczenia stanów zapalnych lub alergicznych | |
| ATE364044T1 (de) | 5ht2c rezeptor agonisten zur behandlung von diabetes und fettleibigkeit | |
| ATE428711T1 (de) | Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon | |
| ATE460413T1 (de) | Substituierte 1-propinoyl-piperazine mit affinität für den mglur5 rezeptor zur behandlung von schmerzzuständen | |
| NO20064238L (no) | Imidazolinderivater med CB1 agonistlsk aktivitet | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| MX2009005541A (es) | Indoles que actuan como antagonistas del receptor v1a. | |
| ATE388939T1 (de) | N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor | |
| ATE365155T1 (de) | 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten | |
| ATE432702T1 (de) | Aminobenzimidazole als selektive melanin- konzentrierende hormon-rezeptorantagonisten zur behandlung von fettsucht und verwandten erkrankungen | |
| ATE438620T1 (de) | Azetidin-derivate als ccr-3-rezeptor-antagonisten | |
| ATE488512T1 (de) | Piperazinderivate als ccr3-hemmer | |
| DE602004010186D1 (de) | Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2 | |
| DE602005012826D1 (de) | Neue mao-b-hemmer | |
| ATE338749T1 (de) | Derivate von 3-phenyl-n-(2-(4-benzyl)piperidin-1- yl)ethyl) acrylamid mit ccr-3-rezeptor antagonistischer wirkung zur verwendung bei der behandlung von entzündungen und allergischen leiden |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1663966 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |